sar425899 sanofi dual agonist glp-1 glucagon Role of a Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor (Twincretin) in Glycemic Control: From Pathophysiology to Treatment Are peptide conjugates the golden

Medicaid coverage for GLP-1 drugs varies significantly by state and plan, with most programs requiring prior authorization and medical documentation of BMI, comorbidities, or failed weight loss attempts

Meanwhile, individuals who took a high-potency GLP-1 drug approved for obesity - such as semaglutide - had greater persistence at 14% three years after initiating therapy.While overall persistence continues to decrease among those taking high-potency GLP-1 produc

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies